Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s shares are listed on the AIM market of the London Stock Exchange under the ABC ticker. Its ADSs are listed on the NASDAQ Global Market under the ABCM ticker.
This area is dedicated to keeping shareholders and potential investors up to date with the share price, news and other relevant information.
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s shares are listed on the AIM market of the London Stock Exchange under the ABC ticker. Its ADSs are listed on the NASDAQ Global Market under the ABCM ticker.
This area is dedicated to keeping shareholders and potential investors up to date with the share price, news and other relevant information.
A review of our performance and governance in 2021
A review of our performance and governance in 2021
A review of our performance and governance in 2020
A review of our performance and governance in 2020
Abcam is a global life sciences company providing highly validated antibodies and biological tools to the life scientist community. The success of our customers’ work, from basic research to translational science, diagnostics and therapeutic clinical programmes, relies on rigorous product quality, performance and reliability.
Operating transparently and responsibly, we manage our business to generate attractive and sustainable long-term economic returns and value for all our stakeholders.
Long-term industry forces across our markets remain attractive, with increases in research funding and capital investment supporting the growth of collaborative and global discovery networks.
Abcam’s goal is to create sustainable social and financial value, by helping accelerate the pace of discovery, and the translation of those discoveries into social impact. We are uniformly committed to responsibly pursuing that goal through our purpose and have a clear strategy to achieve this.
We have a highly experienced Board and Senior Executive Team. The Board is responsible for the Group’s corporate governance, sets the Group’s strategy and policies, has overall responsibility for the oversight of risk and also monitors progress towards meeting its strategic objectives and annual plans. The Board discharges these responsibilities through a programme of meetings and also assesses whether or not, and to what extent, its obligations to the Company’s shareholders and other stakeholders are understood and met. This includes regular reviews of the Group’s financial performance and critical business issues.
https://corporate.abcam.com/wp-content/uploads/2022/03/FY2021-PN.jpg
350
500
Pierre Peotta
/wp-content/uploads/2020/07/logo.png
Pierre Peotta2022-03-14 09:44:502022-03-14 12:12:53Results for the 12- and 18-month periods ended 31 December 2021
https://corporate.abcam.com/wp-content/uploads/2021/01/Flags-PN.jpg
350
500
Pierre Peotta
/wp-content/uploads/2020/07/logo.png
Pierre Peotta2022-02-01 09:32:222022-02-01 09:33:43Trading update for the period ended 31 December 2021
https://corporate.abcam.com/wp-content/uploads/2021/08/GE-v-PN.jpg
350
500
Pierre Peotta
/wp-content/uploads/2020/07/logo.png
Pierre Peotta2021-10-27 07:02:062021-11-09 17:00:21Abcam completes $340m strategic acquisition and expands kit capacity and capability
https://corporate.abcam.com/wp-content/uploads/2021/09/Inv-Pres-news-Sept-2021-BN.jpg
350
500
Pierre Peotta
/wp-content/uploads/2020/07/logo.png
Pierre Peotta2021-09-13 12:29:422021-09-13 12:58:00Interim results for the 6- and 12-month periods ended 30 June 2021
https://corporate.abcam.com/wp-content/uploads/2021/08/GE-v-PN.jpg
350
500
connective
/wp-content/uploads/2020/07/logo.png
connective2021-08-02 07:00:122021-11-09 17:00:25Abcam to acquire BioVision for $340 million
https://corporate.abcam.com/wp-content/uploads/2021/03/Abcam-sign-PN.jpg
350
500
Pierre Peotta
/wp-content/uploads/2020/07/logo.png
Pierre Peotta2021-03-08 12:07:152021-03-08 12:17:51Interim results for the 6 month-period ended 31 December 2020
https://corporate.abcam.com/wp-content/uploads/2021/09/Abcam_Flags-PN.jpg
350
500
Pierre Peotta
/wp-content/uploads/2020/07/logo.png
Pierre Peotta2021-01-11 15:18:342021-09-02 13:13:28Abcam – Half Year Trading Update
https://corporate.abcam.com/wp-content/uploads/2020/10/Abcam-Tower-Pn.jpg
245
350
James Staveley
/wp-content/uploads/2020/07/logo.png
James Staveley2020-10-22 07:00:452021-07-27 15:31:42Abcam Announces Pricing of Offering on NASDAQ
https://corporate.abcam.com/wp-content/uploads/2020/09/abcam-grey-PR-PN-2.png
245
350
James Staveley
/wp-content/uploads/2020/07/logo.png
James Staveley2020-09-14 07:00:422020-11-04 21:33:25Abcam announces Full Year resultsView our latest results and presentations.
Access the latest regulatory news
Stay up to date with investor email alerts.
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Website by FisherPaul